Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor
Sun, A.; Akin, R.S.; Cobos, E.; Smith, J.
Journal of Drugs in Dermatology Jdd 8(4): 395-398
2009
ISSN/ISBN: 1545-9616 PMID: 19363859 Document Number: 630896
Hair depigmentation has been shown to occur with disruption of the interaction between the ligand stem cell factor (SCF) with its class III receptor tyrosine kinase c-kit, also called the stem cell factor receptor. This article reports the case of a patient who experienced depigmentation of her eyelashes, eyebrows, and temporal scalp hair six-to-eight weeks after initiating treatment with dasatinib (BMS-354825 or Sprycel), a novel dual Bcr-Abl/Src family tyrosine kinase inhibitor for chronic myeloid leukemia (CML). This case illustrates a previously unreported side-effect of dasatinib that is most likely due to the drug's inhibition of the c-kit, Src family, and platelet-derived growth factor receptor beta (PDGFRbeta) tyrosine kinases. Further study of hair depigmentation as a side effect of multi-kinase inhibitors can provide useful information on hair and melanocyte physiology.
Document emailed within 1 workday
